Figure 6.

Combination treatment of pharmacological ascorbate and olaparib decreases tumor burden, ascites volume and the non-blood cells number in ascites in vivo. (A) Tumor weights, (B) ascites volume and (C) number of non-blood cells in ascites in the xenograft mouse model treated with vehicle. Asc (4 g/kg i.p., twice daily), olaparib (50 mg/kg, i.p., once daily) or the combination treatment for 25 days. *P<0.05. (D) Body weights of mice throughout the treatment period. Data are presented as the mean ± standard error of mean. (E) Representative hematoxylin and eosin stains of liver, kidney and spleen tissues from each treatment group. Scale bar, 100 µm. Asc, ascorbate; i.p. intraperitoneal.